{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:43:16Z","timestamp":1787755396432,"version":"build-2784847793"},"reference-count":28,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.1016\/j.parkreldis.2011.12.006","type":"journal-article","created":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T04:59:59Z","timestamp":1328590799000},"page":"370-376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Pardoprunox as adjunct therapy to levodopa in patients with Parkinson\u2019s disease experiencing motor fluctuations: Results of a double-blind, randomized, placebo-controlled, trial"],"prefix":"10.1016","volume":"18","author":[{"given":"O.","family":"Rascol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bronzova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.E.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Theeuwes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.V.","family":"van de Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2011.12.006_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1146\/annurev.neuro.22.1.123","article-title":"Etiology and pathogenesis of Parkinson\u2019s disease","volume":"22","author":"Olanow","year":"1999","journal-title":"Annu Rev Neurosci"},{"issue":"Suppl. 3","key":"10.1016\/j.parkreldis.2011.12.006_bib2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ana.10513","article-title":"Limitations of current Parkinson\u2019s disease therapy","volume":"53","author":"Rascol","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2011.12.006_bib3","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1212\/WNL.51.4.1057","article-title":"A\u00a0multicenter trial of ropinirole as adjunct treatment for Parkinson\u2019s disease","volume":"51","author":"Lieberman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2011.12.006_bib4","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson\u2019s disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study): a randomized, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"issue":"Suppl 5","key":"10.1016\/j.parkreldis.2011.12.006_bib5","first-page":"S1","article-title":"An algorithm (decision tree) for the management of Parkinson\u2019s disease treatment guidelines","volume":"56","author":"Olanow","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2011.12.006_bib6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/nature07139","article-title":"On the nature of partial agonism in the nicotinic receptor superfamily","volume":"454","author":"Lape","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.parkreldis.2011.12.006_bib7","series-title":"Parkinson\u2019s disease (solvay pharmaceutical conferences)","first-page":"51","article-title":"SLV308: a novel antiparkinsonian agent with antidepressant and anxiolytic properties","author":"McCreary","year":"2002"},{"issue":"2","key":"10.1016\/j.parkreldis.2011.12.006_bib8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.expneurol.2010.09.007","article-title":"The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesias in MPTP treated common marmosets","volume":"226","author":"Tayarani-Binazir","year":"2010","journal-title":"Exp Neurol"},{"issue":"13","key":"10.1016\/j.parkreldis.2011.12.006_bib9","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/mds.23249","article-title":"Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets","volume":"25","author":"Johnston","year":"2010","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.parkreldis.2011.12.006_bib10","first-page":"40","article-title":"Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson\u2019s disease","volume":"62","author":"Bronzova","year":"2010","journal-title":"Mov Disord"},{"issue":"1","key":"10.1016\/j.parkreldis.2011.12.006_bib11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000216839","article-title":"Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson\u2019s disease","volume":"62","author":"Hauser","year":"2009","journal-title":"Eur Neurol"},{"issue":"8","key":"10.1016\/j.parkreldis.2011.12.006_bib12","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1002\/mds.23590","article-title":"Pardoprunox in early Parkinson\u2019s disease: results from 2 large, randomized double-blind trials","volume":"26","author":"Sampaio","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2011.12.006_bib13","first-page":"165","article-title":"Parkinson\u2019s disease society brain bank, London: overview and research","volume":"39","author":"Daniel","year":"1993","journal-title":"J\u00a0Neural Transm Suppl"},{"issue":"5","key":"10.1016\/j.parkreldis.2011.12.006_bib14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression, and mortality","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.parkreldis.2011.12.006_bib15","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/BF02260863","article-title":"The development and validation of a short measure of functioning and well being for individuals with Parkinson\u2019s disease","volume":"4","author":"Peto","year":"1995","journal-title":"Qual Life Res"},{"issue":"2","key":"10.1016\/j.parkreldis.2011.12.006_bib16","first-page":"CD002261","article-title":"Pramipexole for levodopa-induced complications in Parkinson\u2019s disease","author":"Clarke","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.parkreldis.2011.12.006_bib17","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1212\/WNL.49.1.162","article-title":"Clinical evaluation of pramipexole in advanced Parkinson\u2019s disease: results of a double-blind, placebo-controlled, parallel-group study","volume":"49","author":"Lieberman","year":"1997","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.parkreldis.2011.12.006_bib18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1212\/01.WNL.0000081227.84197.0B","article-title":"Istradefylline US-001 Study Group. randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD","volume":"61","author":"Hauser","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2011.12.006_bib19","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"10.1016\/j.parkreldis.2011.12.006_bib20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/mds.22760","article-title":"Anxious and depressive symptoms in Parkinson\u2019s disease: the French cross-sectionnal DoPaMiP study","volume":"25","author":"N\u00e8gre-Pag\u00e8s","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2011.12.006_bib21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0304-3959(97)00005-5","article-title":"The visual analogue pain intensity scale: what is moderate pain in millimetres?","volume":"72","author":"Collins","year":"1997","journal-title":"PAIN"},{"key":"10.1016\/j.parkreldis.2011.12.006_bib22","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000259516.61938.bb","article-title":"Advanced Parkinson disease treated with rotigotine transdermal system. PREFER study","volume":"68","author":"LeWitt","year":"2007","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.parkreldis.2011.12.006_bib23","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archneur.65.5.577","article-title":"Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson\u2019s disease and motor fluctuations. The ADVANS Study","volume":"65","author":"Rascol","year":"2008","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2011.12.006_bib24","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archneur.62.2.241","article-title":"A\u00a0randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. the PRESTO study","volume":"62","author":"Parkinson Study Group","year":"2005","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.parkreldis.2011.12.006_bib25","first-page":"CD001516","article-title":"Ropinirole for levodopa-induced complications in Parkinson\u2019s disease (Review)","author":"Clarke","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.parkreldis.2011.12.006_bib26","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","article-title":"Pramipexole for the treatment of depressive symptoms in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Barone","year":"2010","journal-title":"Lancet Neurol"},{"issue":"10","key":"10.1016\/j.parkreldis.2011.12.006_bib27","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/mds.22142","article-title":"Chronic pain in Parkinson\u2019s disease: the cross-sectional French DoPaMiP survey","volume":"23","author":"N\u00e8gre-Pag\u00e8s","year":"2008","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.parkreldis.2011.12.006_bib28","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0304-3959(00)00339-0","article-title":"Defining the clinically important difference in pain outcome measures","volume":"88","author":"Farrar","year":"2000","journal-title":"Pain"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802011004317?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802011004317?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:12:52Z","timestamp":1761178372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802011004317"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S1353802011004317"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2011.12.006","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pardoprunox as adjunct therapy to levodopa in patients with Parkinson\u2019s disease experiencing motor fluctuations: Results of a double-blind, randomized, placebo-controlled, trial","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2011.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}